Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wysocki

Showing results (321-330 of 335) with videos related to

Pageof 34
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2015
γδ T Cells Shape Preimmune Peripheral B Cell PopulationsYafei Huang, Andrew Getahun, Ryan A Heiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2014
Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoffRenata Duchnowska, Jeff Sperinde, Ahmed Chenna, et al.
Physical Review Letters|April 15, 2017
Systematic Fuel Cavity Asymmetries in Directly Driven Inertial Confinement Fusion ImplosionsR C Shah, B M Haines, F J Wysocki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast CancerPeter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatmentJeroen W G Derksen, Graham W Warren, Karin Jordan, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
Oncotarget|December 2, 2015
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patientsRenata Duchnowska, Piotr J Wysocki, Konstanty Korski, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|October 17, 2015
The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyGang Zhang, Dongwei Guo, Prasanta K Dash, et al.
Kardiologia Polska|February 20, 2018
[Coordinated heart failure care in Poland: towards optimal organisation of the health care system]Jadwiga Nessler, Adam Kozierkiewicz, Andrzej Gackowski, et al.
Frontiers in Oncology|February 7, 2024
Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practiceMagdalena Knetki-Wróblewska, Rafał Dziadziuszko, Tomasz Jankowski, et al.
Pageof 34

Showing results (321-330 of 335) with videos related to

Sort By:
Pageof 34
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2015
γδ T Cells Shape Preimmune Peripheral B Cell PopulationsYafei Huang, Andrew Getahun, Ryan A Heiser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2014
Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoffRenata Duchnowska, Jeff Sperinde, Ahmed Chenna, et al.
Physical Review Letters|April 15, 2017
Systematic Fuel Cavity Asymmetries in Directly Driven Inertial Confinement Fusion ImplosionsR C Shah, B M Haines, F J Wysocki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2026
Durvalumab Plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast CancerPeter Schmid, Cynthia X Ma, Yeon Hee Park, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatmentJeroen W G Derksen, Graham W Warren, Karin Jordan, et al.
Nature Medicine|January 11, 2022
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Kobe C Yuen, Silke Gillessen, et al.
Oncotarget|December 2, 2015
Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patientsRenata Duchnowska, Piotr J Wysocki, Konstanty Korski, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|October 17, 2015
The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapyGang Zhang, Dongwei Guo, Prasanta K Dash, et al.
Kardiologia Polska|February 20, 2018
[Coordinated heart failure care in Poland: towards optimal organisation of the health care system]Jadwiga Nessler, Adam Kozierkiewicz, Andrzej Gackowski, et al.
Frontiers in Oncology|February 7, 2024
Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practiceMagdalena Knetki-Wróblewska, Rafał Dziadziuszko, Tomasz Jankowski, et al.
Pageof 34